Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山医药集团股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)
(H Share Stock Code: 0874)

THE CHINA SECURITIES REGULATORY COMMISSION'S APPROVAL ON THE ISSUANCE OF OVERSEAS LISTED FOREIGN INVESTED SHARES OF GUANGZHOU PHARMACEUTICALS CO., LTD.

This announcement is made by the board of directors (the "**Board**") of Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (the "**Company**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Hong Kong Stock Exchange**").

INTRODUCTION

Reference is made to the announcements of the Company dated 10 September 2019, 29 April 2020, 17 March 2021 and 31 March 2021, and the circular dated 9 October 2020 in relation to, among other things, the Proposed Spin-off by the Company and overseas listing of Guangzhou Pharmaceuticals Co., Ltd ("GP Corp."), a subsidiary of the Company ("Proposed Spin-off"). Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the announcements.

THE CSRC'S APPROVAL ON THE ISSUANCE OF OVERSEAS LISTED FOREIGN INVESTED SHARES OF GP CORP.

The Board is pleased to announce that, on 2 July 2021, GP Corp. received the Approval on the Issuance of Overseas Listed Foreign Invested Shares of Guangzhou Pharmaceuticals Co., Ltd. (Zheng Jian Xu Ke [2021] No. 2187) from the China Securities Regulatory Commission ("CSRC") with the approvals as follows:

i. GP Corp. is approved with the new issuance of no more than 938,900,442 overseas listed foreign invested shares of RMB 1.00 per share, all being ordinary shares. Upon the issuance, GP Corp. could be listed on the Main Board of the Hong Kong Stock Exchange.

- ii. Within 15 working days after its listing, the non-overseas listed shares of GP Corp. shall be centrally registered with and in custody of the China Securities Depository and Clearing Corporation Ltd., and GP Corp. shall report in writing to the CSRC on matters relating to the centralized registration and custody of its non-overseas listed shares and its issuance and listing.
- iii. The approval shall be valid for 12 months as of the date of approval.
- iv. In its process of issuance of shares and listing, GP Corp. shall strictly comply with the relevant domestic and foreign laws, regulations and rules.

GENERAL

As the Listing is conditional upon the approval of the Hong Kong Stock Exchange Listing Committee, the final decision of the Company and GP Corp., market conditions and other considerations, shareholders and potential investors of the Company should be aware that there is no assurance from the Company that the Proposed Spin-off will take place or as to when it may take place. Shareholders and potential investors of the Company should therefore exercise caution when dealing in or investing in the shares or other securities of the Company. Any person who is in doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional advisers.

The Company will make further announcement(s) in relation to the Proposed Spin-off as and when appropriate.

The Board of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 4 July 2021

As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Mr. Yang Jun, Ms. Cheng Ning, Ms. Liu Juyan, Mr. Li Hong, Mr. Wu Changhai and Mr. Zhang Chunbo as executive Directors, and Mr. Wong Hin Wing, Ms. Wang Weihong, Mr. Chen Yajin and Mr. Huang Min as independent non-executive Directors.